Kantos Master

Formoterol fumarate and beclometasone dipropionate, the active ingredients in Kantos Master, are a combination inhaled corticosteroid and long‑acting β2‑agonist presented as an inhalation aerosol (metered‑dose inhaler) for inhalation use. They treat asthma and chronic obstructive pulmonary disease in adults and adolescents, providing anti‑inflammatory and bronchodilatory actions that help maintain airway patency and reduce exacerbations.

GNH USA supplies Kantos Master as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Kantos Master combines an inhaled corticosteroid with a long‑acting β2‑agonist to manage obstructive airway diseases.

Asthma: improves symptom control and reduces the frequency of exacerbations. COPD: enhances lung function and decreases dyspnea during daily activities. Chronic bronchitis (COPD component): reduces cough and sputum production, improving quality of life.

Common Side Effects: - Throat irritation or hoarseness. - Oral candidiasis (thrush). - Cough after inhalation. - Headache.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Adrenal suppression with prolonged high‑dose use. - Severe allergic reactions, including anaphylaxis. - Cardiac arrhythmias or tachycardia.

Kantos Master should be used under medical supervision with attention to the following precautions. - Assess asthma or COPD control before initiating therapy. - Monitor for oral thrush and advise rinsing the mouth after each inhalation. - Avoid abrupt discontinuation; taper if used at high doses for a long period. - Use with caution in patients with cardiovascular disease. - Use with caution during pregnancy and lactation (category unknown). - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Kantos Master may interact with other medicines; relevant interactions are grouped below. Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and precipitate bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase systemic corticosteroid exposure. Moderate Interactions (Monitor Closely): - Theophylline: may increase plasma concentrations; monitor levels. - Diuretics: monitor potassium as LABA can cause hypokalemia. - Ritonavir or other potent CYP3A4 inhibitors: may raise steroid levels, watch for systemic effects.